` MRNA (Moderna Inc) vs S&P 500 Comparison - Alpha Spread

MRNA
vs
S&P 500

Over the past 12 months, MRNA has underperformed S&P 500, delivering a return of -78% compared to the S&P 500's 9% growth.

Stocks Performance
MRNA vs S&P 500

Loading

Performance Gap
MRNA vs S&P 500

Loading
MRNA
S&P 500
Difference

Performance By Year
MRNA vs S&P 500

Loading
MRNA
S&P 500
Add Stock

Competitors Performance
Moderna Inc vs Peers

S&P 500
MRNA
ABBV
AMGN
GILD
VRTX
Add Stock

Moderna Inc
Glance View

Economic Moat
None
Market Cap
10.4B USD
Industry
Biotechnology

In the vibrant world of biotechnology, Moderna Inc. stands as a remarkable testament to the fusion of cutting-edge science and swift innovation. Founded in 2010 and based in Cambridge, Massachusetts, Moderna has crafted its niche in messenger RNA (mRNA) technology, pivoting the traditional paradigms of drug development. The company’s unique approach utilizes synthetic mRNA to direct cells in the body to produce proteins that can prevent, treat, or cure diseases. This innovative platform enables rapid testing and development of medicines across a wide array of therapeutic areas, from infectious diseases to oncology, leveraging its flexible technology to address significant unmet medical needs. Moderna’s story gained global prominence in the context of the COVID-19 pandemic, when its vaccine, one of the first to be authorized, became crucial in combatting the virus, highlighting the potential of mRNA technology on a global stage. Financially, Moderna’s business model is driven by a combination of strategic partnerships, robust research and development capabilities, and the commercialization of its mRNA products. The company collaborates extensively with government agencies, global health organizations, and biopharmaceutical enterprises to both advance its pipeline and maximize its market reach. Revenue is primarily generated through the sale of its COVID-19 vaccine, alongside income from grants and collaboration agreements. Moreover, Moderna continually invests in expanding its mRNA platform and portfolio, seeking long-term value creation by targeting diverse therapeutic areas such as rare diseases, autoimmune disorders, and personalized cancer vaccines. By reinvesting in innovation and scaling its manufacturing capabilities, Moderna is not just a quintessential biotech enterprise but a harbinger of a new era in medical science.

MRNA Intrinsic Value
33.89 USD
Undervaluation 20%
Intrinsic Value
Price
Back to Top